The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab

Neurology. 2018 Sep 18;91(12):572-573. doi: 10.1212/WNL.0000000000006213.

Authors

Aravindhan Baheerathan¹, Cillian McNamara², Sabrina Kalam², Neil Rane², Tara D Barwick², Helen Grote², Richard Nicholas²

Affiliations

¹ From the Departments of Neurology (A.B., S.K., H.G., R.N.), Neuroradiology (C.M., N.R.), and Nuclear Medicine (T.D.B.), Charing Cross Hospital, Imperial College NHS Trust, London, UK. [email protected].
² From the Departments of Neurology (A.B., S.K., H.G., R.N.), Neuroradiology (C.M., N.R.), and Nuclear Medicine (T.D.B.), Charing Cross Hospital, Imperial College NHS Trust, London, UK.

No abstract available

Publication types

Case Reports

MeSH terms

Diagnosis, Differential
Female
Fluorodeoxyglucose F18*
Humans
Immune Reconstitution Inflammatory Syndrome / chemically induced
Immune Reconstitution Inflammatory Syndrome / complications
Immune Reconstitution Inflammatory Syndrome / diagnostic imaging*
Leukoencephalopathy, Progressive Multifocal / chemically induced
Leukoencephalopathy, Progressive Multifocal / complications
Leukoencephalopathy, Progressive Multifocal / diagnostic imaging*
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / diagnostic imaging*
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Natalizumab / adverse effects*
Natalizumab / therapeutic use
Positron-Emission Tomography*

Substances

Natalizumab
Fluorodeoxyglucose F18